Biogen Current Ratio 2010-2022 | BIIB

Current and historical current ratio for Biogen (BIIB) from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Biogen current ratio for the three months ending June 30, 2022 was 1.94.
Biogen Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-06-30 $9.74B $5.02B 1.94
2022-03-31 $7.92B $3.95B 2.01
2021-12-31 $7.86B $4.30B 1.83
2021-09-30 $7.16B $4.21B 1.70
2021-06-30 $7.18B $3.35B 2.15
2021-03-31 $6.72B $3.17B 2.12
2020-12-31 $6.89B $3.74B 1.84
2020-09-30 $7.84B $3.80B 2.06
2020-06-30 $8.49B $3.45B 2.46
2020-03-31 $8.01B $4.64B 1.73
2019-12-31 $8.38B $4.86B 1.72
2019-09-30 $8.45B $4.43B 1.91
2019-06-30 $7.91B $3.21B 2.46
2019-03-31 $8.94B $3.15B 2.84
2018-12-31 $7.64B $3.30B 2.32
2018-09-30 $8.72B $3.18B 2.75
2018-06-30 $7.43B $3.15B 2.36
2018-03-31 $10.20B $3.15B 3.23
2017-12-31 $7.87B $3.37B 2.34
2017-09-30 $7.57B $3.45B 2.20
2017-06-30 $7.11B $3.38B 2.10
2017-03-31 $6.86B $2.99B 2.29
2016-12-31 $8.73B $3.42B 2.55
2016-09-30 $8.09B $2.50B 3.24
2016-06-30 $7.45B $2.52B 2.96
2016-03-31 $7.20B $2.78B 2.59
2015-12-31 $6.70B $2.58B 2.60
2015-09-30 $9.27B $2.63B 3.52
2015-06-30 $5.62B $2.56B 2.20
2015-03-31 $5.26B $1.95B 2.70
2014-12-31 $4.54B $2.22B 2.05
2014-09-30 $4.37B $1.94B 2.25
2014-06-30 $3.93B $1.92B 2.05
2014-03-31 $3.53B $1.59B 2.21
2013-12-31 $3.19B $1.76B 1.81
2013-09-30 $2.64B $1.52B 1.74
2013-06-30 $2.52B $1.30B 1.94
2013-03-31 $5.33B $1.28B 4.16
2012-12-31 $3.24B $1.66B 1.96
2012-09-30 $3.06B $1.52B 2.01
2012-06-30 $2.87B $1.43B 2.00
2012-03-31 $2.68B $1.34B 2.00
2011-12-31 $2.98B $0.91B 3.26
2011-09-30 $2.84B $0.89B 3.21
2011-06-30 $2.69B $0.95B 2.82
2011-03-31 $2.63B $0.98B 2.69
2010-12-31 $2.54B $1.05B 2.42
2010-09-30 $2.13B $0.82B 2.59
2010-06-30 $2.26B $0.76B 2.98
2010-03-31 $2.41B $0.68B 3.53
2009-12-31 $2.48B $0.72B 3.47
2009-09-30 $2.57B $0.72B 3.57
2009-06-30 $2.74B $0.80B 3.41
2009-03-31 $2.48B $0.81B 3.07
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $38.353B $10.982B
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $150.600B 9.14
GSK (GSK) United Kingdom $61.519B 7.39
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.876B 0.00
QIAGEN (QGEN) Netherlands $9.539B 15.97
Ginkgo Bioworks Holdings (DNA) United States $5.604B 0.00
Myovant Sciences (MYOV) United Kingdom $2.344B 0.00
Arcus Biosciences (RCUS) United States $1.891B 36.90
Emergent Biosolutions (EBS) United States $1.051B 6.09
ADC Therapeutics SA (ADCT) Switzerland $0.371B 0.00
Zymeworks (ZYME) Canada $0.344B 0.00
Enzo Biochem (ENZ) United States $0.115B 0.00
Gelesis Holdings (GLS) United States $0.082B 0.00
SQZ Biotechnologies (SQZ) United States $0.067B 0.00
Ambrx Biopharma (AMAM) United States $0.042B 0.00